DexCom, Inc. (DXCM) Stake Raised by DF Dent & Co. Inc.

DF Dent & Co. Inc. lifted its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 46.2% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 14,094 shares of the medical device company’s stock after purchasing an additional 4,455 shares during the period. DF Dent & Co. Inc.’s holdings in DexCom were worth $1,031,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in the company. Independent Portfolio Consultants Inc. lifted its position in shares of DexCom by 0.4% during the 2nd quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock worth $183,000 after purchasing an additional 9 shares during the last quarter. Bbva Compass Bancshares Inc. lifted its position in shares of DexCom by 1.9% during the 2nd quarter. Bbva Compass Bancshares Inc. now owns 3,670 shares of the medical device company’s stock worth $268,000 after purchasing an additional 69 shares during the last quarter. Public Employees Retirement Association of Colorado lifted its position in shares of DexCom by 0.4% during the 2nd quarter. Public Employees Retirement Association of Colorado now owns 18,613 shares of the medical device company’s stock worth $1,362,000 after purchasing an additional 83 shares during the last quarter. King Luther Capital Management Corp lifted its position in shares of DexCom by 0.7% during the 1st quarter. King Luther Capital Management Corp now owns 12,105 shares of the medical device company’s stock worth $1,026,000 after purchasing an additional 90 shares during the last quarter. Finally, World Asset Management Inc lifted its position in shares of DexCom by 4.1% during the 2nd quarter. World Asset Management Inc now owns 3,901 shares of the medical device company’s stock worth $285,000 after purchasing an additional 155 shares during the last quarter.

In related news, CEO Kevin R. Sayer sold 6,000 shares of the stock in a transaction dated Friday, August 11th. The shares were sold at an average price of $69.77, for a total value of $418,620.00. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction dated Monday, July 24th. The stock was sold at an average price of $69.47, for a total transaction of $100,731.50. The disclosure for this sale can be found here. Insiders have sold 23,023 shares of company stock worth $1,625,018 over the last three months. 1.70% of the stock is owned by corporate insiders.

DXCM has been the subject of several recent analyst reports. Northland Securities cut shares of DexCom from an “outperform” rating to a “market perform” rating and decreased their price objective for the stock from $85.00 to $60.00 in a research report on Thursday, September 28th. Robert W. Baird reaffirmed a “hold” rating and set a $79.00 price objective on shares of DexCom in a research report on Sunday, September 10th. Wedbush reaffirmed an “outperform” rating and set a $76.00 price objective (down from $85.00) on shares of DexCom in a research report on Thursday, September 28th. BidaskClub raised shares of DexCom from a “hold” rating to a “buy” rating in a research report on Wednesday, June 21st. Finally, Barclays PLC initiated coverage on shares of DexCom in a research note on Friday, September 15th. They set an “equal weight” rating and a $76.00 price target on the stock. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have assigned a buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $72.19.

DexCom, Inc. (NASDAQ DXCM) traded up 1.52% on Wednesday, reaching $46.80. 355,649 shares of the company’s stock were exchanged. The stock’s 50 day moving average price is $66.16 and its 200 day moving average price is $71.48. The firm’s market capitalization is $4.05 billion. DexCom, Inc. has a 1-year low of $42.62 and a 1-year high of $88.80.

DexCom (NASDAQ:DXCM) last issued its earnings results on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.07. The company had revenue of $170.60 million for the quarter, compared to analysts’ expectations of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The firm’s revenue was up 24.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.24) earnings per share. On average, analysts expect that DexCom, Inc. will post ($0.80) earnings per share for the current year.

COPYRIGHT VIOLATION WARNING: “DexCom, Inc. (DXCM) Stake Raised by DF Dent & Co. Inc.” was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this news story on another site, it was illegally copied and republished in violation of U.S. & international copyright & trademark legislation. The correct version of this news story can be read at https://www.com-unik.info/2017/10/11/dexcom-inc-dxcm-stake-raised-by-df-dent-co-inc.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

What are top analysts saying about DexCom Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for DexCom Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit